[ad_1] MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named…
Tag: Telix Pharmaceuticals Limited
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
[ad_1] MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase…
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
[ad_1] MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM)…
First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
[ad_1] MELBOURNE, Australia, Nov. 12, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s Phase III…
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
[ad_1] MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Denmark-based WIIK Pharma ApS (Wiik Pharma)…
ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
[ad_1] The study has achieved its primary objectives, confirming the safety and tolerability profile of TLX591 administered in two doses, two weeks apart in combination with standard of care (SoC)…
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
[ad_1] MELBOURNE, Australia, Aug. 23, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2023. All figures…
Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer
[ad_1] June 21, 2023, at The Yale Club, New York City Featured speakers and Key Opinion Leaders include: Dr Christian Behrenbruch, Dr Colin Hayward, Kevin Richardson, Dr Brian Shuch and…
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
[ad_1] MELBOURNE, Australia, May 7, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to…
Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented in “Game Changing” Session at EAU
[ad_1] MELBOURNE, Australia, March 13, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of…